Engineered synthesis, processing, and in-vivo performance of multicancer drug nanocapsules

M. Khan, A. Yamasta, M.D. Mahmudul Hassan, M. Parvinand, M. Rashid, A. Arbab,
United States

Keywords: coaxial electrosprying, nanocapsules, cancer


A coaxial electrospraying processing of injectable nanocapsules with multiple cancer drugs for target nanoscale drug delivery has been investigated. Primary and metastatic breast cancer tumor microenvironment were targeted for controlled delivery. The therapeutic performance of the nanocapsules were tested in in vitro and in vivo. Multiple cancer drugs (Paclitaxel and GW2580) as core and Polycaprolactam (PCL) as shell has been used to produce multicancer drug nanocapsules. The nanocapsules were in the size of less than 100 nm. A coaxial spinneret with Y connector was used to have distinct flow of drugs and polymer to continuously encapsulate nanoscale cancer drugs and produce injectable multicancer drug nanocapsules. Both the drugs and the polymer solution were exposed to very high voltage (40 -44KV) during the production of the nanocapsules. The relative polymer to drug ratio and the drug doses were controlled by the solution concentration and the precession flow rate control. In the produced multidrug nanocapsules, the ratio of Paclitaxel to GW2580 was 1:8 while the ratio of the total drugs in the core to polymer in the sheath was 1:4. SEM and TEM studies showed no presence of drug components at the outer sheath as well as distinct drug phase at the core, which indicate the encapsulation of the two drugs at nanoscale. Moreover, NGR peptides were tagged with the nanocapsules for active receptor targeting. In vitro and in vivo tests showed nanoparticles performance on cell viability and animal survival on breast cancer model.